Abstract
Background and Objective
Background • CDC reports half of patients admitted to the hospital received at least 1 dose of antibiotics from 2006-2012 • Approximately 32 million people in the United States have a documented allergy to a beta-lactam (BL) antibiotic • Approximately 10% of all US patients report having an allergic reaction to a BL in their lifetime • Fewer than 1% has a true IgE (immunoglobulin E) mediated allergy to a BL • Over 80% of those patients with an IgE-mediated allergy lose sensitivity after 10 years • Penicillin-skin testing cost: ~$220 • Per the CDC, carbapenem use increased by 37% from 2006-2012 • Carbapenems are rarely first line antibiotics, but are frequently used when first line agents are excluded due to the patient's drug-allergies • Carbapenem use is associated with increased healthcare costs and promotion of antibiotic resistance Objective • Determine the beta-lactam (BL) allergy-risk stratification for patients at Parkview Regional Medical Center with a documented allergy to a BL.
Document Type
Article
Publication Date
2020
Recommended Citation
Brown, Zachary PharmD; Walker, Dylan; and Towne, Trent PharmD, BCPS, "Evaluation of beta-lactam allergy classification and carbapenem use in patients admitted to the medical-surgical floors of a large, community hospital" (2020). Parkview Pharmacy Department. 41.
https://researchrepository.parkviewhealth.org/pharma/41